CD33 and acute myeloid leukemia: Gemtuzumab ozogamicin (Wyeth/Pfizer) received accelerated approval for relapsed CD33+ acute myeloid leukemia (AML) in 2000 but was voluntarily withdrawn from the market in 2010 after post-marketing studies.